Follicular lymphoma is a diverse disease, both biologically and clinically. Patients may present with indolent, asymptomatic disease or more aggressive, symptomatic disease with high tumor burden.

My annual scan showed no cancer recurrence, but revealed some minor issues related to aging and potential fibroids, requiring ...

Novartis' CAR-T Kymriah has become the first therapy in the category to be approved for the treatment of relapsed/refractory follicular lymphoma, ahead of Gilead Sciences' rival Yescarta.

For evaluating response to treatment for follicular lymphoma, computed tomography (CT) has been considered the gold standard, and most clinical studies and trials have used CT as a tool for ...